INDERIDE LA 80/50 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Inderide La 80/50, and when can generic versions of Inderide La 80/50 launch?
Inderide La 80/50 is a drug marketed by Wyeth Ayerst and is included in one NDA.
The generic ingredient in INDERIDE LA 80/50 is hydrochlorothiazide; propranolol hydrochloride. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; propranolol hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for INDERIDE LA 80/50?
- What are the global sales for INDERIDE LA 80/50?
- What is Average Wholesale Price for INDERIDE LA 80/50?
Summary for INDERIDE LA 80/50
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | INDERIDE LA 80/50 at DailyMed |
US Patents and Regulatory Information for INDERIDE LA 80/50
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wyeth Ayerst | INDERIDE LA 80/50 | hydrochlorothiazide; propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 019059-001 | Jul 3, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for INDERIDE LA 80/50
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Wyeth Ayerst | INDERIDE LA 80/50 | hydrochlorothiazide; propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 019059-001 | Jul 3, 1985 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for INDERIDE LA 80/50
See the table below for patents covering INDERIDE LA 80/50 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Netherlands | 7805510 | ⤷ Sign Up | |
Ireland | 45578 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION | ⤷ Sign Up |
Switzerland | 638399 | PHARMAZEUTISCHES PRAEPARAT MIT VERZOEGERTER WIRKSTOFFABGABE. | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for INDERIDE LA 80/50
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0454511 | SPC/GB99/008 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 |
0502314 | SPC/GB02/037 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419 |
0502314 | C300095 | Netherlands | ⤷ Sign Up | PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |